Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
British journal of haematology 2011 Jul 154 (2): 223-8.
Treon Steven P, Yang Guang, Hanzis Christine, Ioakimidis Leukothea, Verselis Sigitas J, Fox Edward A, Xu Lian, Hunter Zachary R, Tseng Hsiuyi, Manning Robert J, Patterson Christopher J, Sheehy Patricia, Turnbull Bar
- Page last reviewed:Mar 1, 2018
- Page last updated:Jun 20, 2019
- Content source: